Table 2. Progress of each patient during hospital admission.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sex/age, years | F/28 | M/54 | M/33 | F/57 | F/52 | M/39 | M/52 | M/60 | F/55 | F/50 |
| Country of infection | Korea | Korea | Korea | Korea | Korea | Philippines | Korea | Korea | UK | Korea |
| Underlying respiratory disease | None | None | None | None | None | None | None | None | None | None |
| Other comorbidity | None | Hypertension, dyslipidemia, GERD, alcoholic fatty liver | Hypertension | None | None | None | None | Hypertension | Hydatidiform mole | Rt. Renal cyst |
| Smoking history | None | Ex-smoker | None | None | None | Current smoker | None | Ex-smoker | None | None |
| Symptoms | Fever, cough | Cough, sore throat | Fever | Fever, chills, sputum sore throat, myalgia | Fever, chills, myalgia | Fever, chills, myalgia | Fever, cough, shortness of breath | Cough, rhinorrhea | Fever, shortness of breath, sore throat, nausea | Fever, cough, sputum, sore throat, myalgia, fatigue |
| Duration of illnessa, days | 4 | 1 | 3 | 9 | 4 | 4 | 11 | 8 | 27 | 4 |
| Chest CT findings | Bilateral GGO | Unilateral GGO | Bilateral GGO | Bilateral GGO | Bilateral GGO | Unilateral GGO | Bilateral GGO, bilateral consolidations | Bilateral GGO | Bilateral GGOs | Unilateral GGO |
| Bilateral consolidations | ||||||||||
| Other antiviral agents used for COVID-19, days | Lopinavir/ritonavir (2) | Lopinavir/ritonavir (8) | Lopinavir/ritonavir (2) | Lopinavir/ritonavir (2) | Lopinavir/ritonavir (7) | Lopinavir/ritonavir (2) | Lopinavir/ritonavir (3) | Lopinavir/ritonavir (5) | Lopinavir/Ritonavir (10) | Lopinavir/Ritonavir (2) |
| Ciclesonide (10) | HCQ (2) | |||||||||
| Interval between symptom onset and starting RDV, days | 6 | 9 | 5 | 11 | 14 | 6 | 13 | 13 | 28 | 6 |
| Duration of RDV, days | 10 | 5 | 10 | 5 | 5 | 5 | 10 | 5 | 10 | 5 |
| AE during RDV | None | None | Diarrhea (G1), AST, ALT elevation (G1) | Nausea (G2), chest discomfort (G2) | None | AST, ALT elevation (G1), insomnia (G1) | AST, ALT elevation (G2) | None | AST, ALT elevation (G1), nausea (G1) | AST, ALT elevation (G2), nausea (G2) |
| ICU care | No | Yes | No | No | No | No | Yes | No | Yes | No |
| Respiratory support modalityb | None | MV | None | Nasal O2 | None | None | Nasal O2 | Nasal O2 | HFNC | None |
| Vasopressor | No | Norepinephrine | No | No | No | No | No | No | No | No |
| ECMO | No | No | No | No | No | No | No | No | No | No |
| Hemodialysis | No | No | No | No | No | No | No | No | No | No |
| Antibiotics | No | Moxifloxacin, piperacillin/tazobactam, teicoplanin, meropenem, ampicillin/sulbactam, minocycline | No | No | No | No | Ceftriaxone, azithromycin, moxifloxacin | No | Moxifloxacin | No |
| Use of steroids | No | Yes | No | No | No | No | No | No | No | No |
| Time to negative PCR, daysc | N/A | 29 (21) | N/A | N/A | 20 (7) | 17 (12) | 23 (11) | N/A | N/A | N/A |
| Prognosis | Transferred | On admission | Transferred | On admission | Discharged | Discharged | Discharged | On admission | On admission | On admission |
aTime from onset of COVID-19-related symptoms and hospital admission.
bHighest level of respiratory support during hospital admission.
cTime from onset of COVID-19-related symptoms to confirmation of a first negative SARS-CoV-2 PCR result. Time from start of RDV to confirmation of a negative SARS-CoV-2 PCR result is given in parentheses.
F, female; M, male; GERD, gastroesophageal reflux disease; CT, computed tomography; GGO, ground glass opacity; COVID-19, coronavirus disease 2019; HCQ, hydroxychloroquine; RDV, remdesivir; AE, adverse event; G, grade; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ICU, intensive care unit; MV, mechanical ventilation; HFNC, high flow nasal cannula; ECMO, extracorporeal membrane oxygenation; PCR, polymerase chain reaction; N/A, not applicable.